EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer
Read time: 1 mins
Last updated:25th Jun 2014
EUCROSS is a phase II trial to evaluate the efficacy and safety of crizotinib in patients with adenocarcinoma of the lung harbouring ROS1 translocations. Patients will be treated with 250mg crizotinib bid untill progression or intolerable toxicity.
|Study start date||2014-06-25|